These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29996737)

  • 21. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
    Lim KJC; Tam CS
    Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
    Ferrero S; Gentile M; Laurenti L; Mauro FR; Martelli M; Sportoletti P; Visco C; Zinzani PL; Tedeschi A; Varettoni M
    Hematol Oncol; 2022 Aug; 40(3):332-340. PubMed ID: 35212014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
    Treon SP; Sarosiek S; Castillo JJ
    Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
    Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
    Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more.
    Tohidi-Esfahani I; Trotman J
    Br J Haematol; 2023 Jun; 201(5):807-808. PubMed ID: 36715656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
    Owen RG; McCarthy H; Rule S; D'Sa S; Thomas SK; Tournilhac O; Forconi F; Kersten MJ; Zinzani PL; Iyengar S; Kothari J; Minnema MC; Kastritis E; Aurran-Schleinitz T; Cheson BD; Walter H; Greenwald D; Chen DY; Frigault MM; Hamdy A; Izumi R; Patel P; Wei H; Lee SK; Mittag D; Furman RR
    Lancet Haematol; 2020 Feb; 7(2):e112-e121. PubMed ID: 31866281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
    Castellani F; Visentin A; Campagnolo M; Salvalaggio A; Cacciavillani M; Candiotto C; Bertorelle R; Trentin L; Briani C
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32284437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
    Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
    Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
    [No Abstract]   [Full Text] [Related]  

  • 35.
    Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
    Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
    [No Abstract]   [Full Text] [Related]  

  • 36. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
    Tripathi A; Steingart R
    J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
    [No Abstract]   [Full Text] [Related]  

  • 37. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
    Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
    Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
    Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
    Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
    Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.